These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18574017)

  • 21. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
    Trissel LA; Gilbert DL; Martinez JF
    Am J Health Syst Pharm; 1997 Dec; 54(23):2708-13. PubMed ID: 9408515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
    Psathas PA; Kuzmission A; Ikeda K; Yasuo S
    Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
    Trissel LA; Saenz CA; Ogundele AB; Ingram DS
    Am J Health Syst Pharm; 2004 Nov; 61(21):2289-93. PubMed ID: 15552637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
    Lu J; Liu Q; Kupiec TC; Vail H; Lynch LR; Fam DS; Vu NT
    Int J Pharm Compd; 2021; 25(1):52-61. PubMed ID: 33503010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stability of doripenem in polyvinyl chloride bags and elastomeric pumps.
    Crandon JL; Sutherland C; Nicolau DP
    Am J Health Syst Pharm; 2010 Sep; 67(18):1539-44. PubMed ID: 20811032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
    Asempa TE; Avery LM; Kidd JM; Kuti JL; Nicolau DP
    Am J Health Syst Pharm; 2018 Jul; 75(14):1048-1056. PubMed ID: 29895521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Mar; 51(5):672-8. PubMed ID: 8203388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions.
    Martinez JF; Trissel LA; Gilbert DL
    Int J Pharm Compd; 1997; 1(5):356-8. PubMed ID: 23989380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compatibility of micafungin injection with other drugs during simulated y-site co-administration.
    Trusley C; Kupiec TC; Trissel LA
    Int J Pharm Compd; 2006; 10(3):230-3. PubMed ID: 23974236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
    Trissel LA; Gilbert DL; Martinez JF
    Am J Health Syst Pharm; 1997 Jun; 54(11):1287-92. PubMed ID: 9179349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Feb; 51(4):495-9. PubMed ID: 8017415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
    Kupie TC; Trusley C; Ben M; Trissel LA
    Am J Health Syst Pharm; 2008 Sep; 65(18):1735-59. PubMed ID: 18769000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
    Monogue ML; Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Am J Health Syst Pharm; 2018 Jan; 75(1):e36-e44. PubMed ID: 29273611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compatibility of aztreonam with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1995 May; 52(10):1086-90. PubMed ID: 7656099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
    Trissel LA; Gilbert DL; Martinez JF; Baker MB; Walter WV; Mirtallo JM
    Am J Health Syst Pharm; 1997 Jun; 54(11):1295-300. PubMed ID: 9179351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1993 Nov; 50(11):2359-63. PubMed ID: 8266963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
    Trissel LA; Gilbert DL; Martinez JF; Kim MC
    Am J Health Syst Pharm; 1997 Oct; 54(19):2192-6. PubMed ID: 9331439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability and compatibility of granisetron hydrochloride in i.v. solutions and oral liquids and during simulated Y-site injection with selected drugs.
    Mayron D; Gennaro AR
    Am J Health Syst Pharm; 1996 Feb; 53(3):294-304. PubMed ID: 8808027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam.
    Wade J; Cooper M; Ragan R
    Hosp Pharm; 2015 May; 50(5):376-9. PubMed ID: 26405323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
    Trissel LA; Bready BB
    Am J Hosp Pharm; 1992 Jul; 49(7):1716-9. PubMed ID: 1352424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.